Advertisement

Research ArticleCell biology Free access | 10.1172/JCI38263

Essential role of the RNA-binding protein HuR in progenitor cell survival in mice

Mallika Ghosh,1 Hector Leonardo Aguila,2 Jason Michaud,1 Youxi Ai,1 Ming-Tao Wu,1 Annabrita Hemmes,3 Ari Ristimaki,3,4 Caiying Guo,5 Henry Furneaux,1,6 and Timothy Hla1,7

1Center for Vascular Biology and 2Department of Immunology, University of Connecticut Health Center, Farmington, Connecticut, USA. 3Department of Pathology, HUSLAB, and Haartman Institute, Helsinki University Central Hospital, and Genome-Scale Biology Research Program, University of Helsinki, Helsinki, Finland. 4Department of Pathology, Division of Diagnostics, University of Oulu, and Oulu University Hospital, Oulu, Finland. 5Janelia Farm Campus, Howard Hughes Medical Institute, Reston, Virginia, USA. 6Department of Molecular, Microbial, and Structural Biology, University of Connecticut Health Center, Farmington, Connecticut, USA. 7Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.

Address correspondence to: Timothy Hla, Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Box 69, 1300 York Avenue, New York, New York, USA. Phone: (212) 746-9953; Fax: (212) 746-2830; E-mail: tih2002@med.cornell.edu. Or to: Hector Leonardo Aguila, Department of Immunology, University of Connecticut Health Center, 263 Farmington Ave., Farmington, Connecticut 06030, USA. Phone: (860) 679-7658; Fax: (860) 679-8130; E-mail: aguila@nso1.uchc.edu.

Find articles by Ghosh, M. in: JCI | PubMed | Google Scholar

1Center for Vascular Biology and 2Department of Immunology, University of Connecticut Health Center, Farmington, Connecticut, USA. 3Department of Pathology, HUSLAB, and Haartman Institute, Helsinki University Central Hospital, and Genome-Scale Biology Research Program, University of Helsinki, Helsinki, Finland. 4Department of Pathology, Division of Diagnostics, University of Oulu, and Oulu University Hospital, Oulu, Finland. 5Janelia Farm Campus, Howard Hughes Medical Institute, Reston, Virginia, USA. 6Department of Molecular, Microbial, and Structural Biology, University of Connecticut Health Center, Farmington, Connecticut, USA. 7Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.

Address correspondence to: Timothy Hla, Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Box 69, 1300 York Avenue, New York, New York, USA. Phone: (212) 746-9953; Fax: (212) 746-2830; E-mail: tih2002@med.cornell.edu. Or to: Hector Leonardo Aguila, Department of Immunology, University of Connecticut Health Center, 263 Farmington Ave., Farmington, Connecticut 06030, USA. Phone: (860) 679-7658; Fax: (860) 679-8130; E-mail: aguila@nso1.uchc.edu.

Find articles by Aguila, H. in: JCI | PubMed | Google Scholar

1Center for Vascular Biology and 2Department of Immunology, University of Connecticut Health Center, Farmington, Connecticut, USA. 3Department of Pathology, HUSLAB, and Haartman Institute, Helsinki University Central Hospital, and Genome-Scale Biology Research Program, University of Helsinki, Helsinki, Finland. 4Department of Pathology, Division of Diagnostics, University of Oulu, and Oulu University Hospital, Oulu, Finland. 5Janelia Farm Campus, Howard Hughes Medical Institute, Reston, Virginia, USA. 6Department of Molecular, Microbial, and Structural Biology, University of Connecticut Health Center, Farmington, Connecticut, USA. 7Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.

Address correspondence to: Timothy Hla, Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Box 69, 1300 York Avenue, New York, New York, USA. Phone: (212) 746-9953; Fax: (212) 746-2830; E-mail: tih2002@med.cornell.edu. Or to: Hector Leonardo Aguila, Department of Immunology, University of Connecticut Health Center, 263 Farmington Ave., Farmington, Connecticut 06030, USA. Phone: (860) 679-7658; Fax: (860) 679-8130; E-mail: aguila@nso1.uchc.edu.

Find articles by Michaud, J. in: JCI | PubMed | Google Scholar

1Center for Vascular Biology and 2Department of Immunology, University of Connecticut Health Center, Farmington, Connecticut, USA. 3Department of Pathology, HUSLAB, and Haartman Institute, Helsinki University Central Hospital, and Genome-Scale Biology Research Program, University of Helsinki, Helsinki, Finland. 4Department of Pathology, Division of Diagnostics, University of Oulu, and Oulu University Hospital, Oulu, Finland. 5Janelia Farm Campus, Howard Hughes Medical Institute, Reston, Virginia, USA. 6Department of Molecular, Microbial, and Structural Biology, University of Connecticut Health Center, Farmington, Connecticut, USA. 7Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.

Address correspondence to: Timothy Hla, Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Box 69, 1300 York Avenue, New York, New York, USA. Phone: (212) 746-9953; Fax: (212) 746-2830; E-mail: tih2002@med.cornell.edu. Or to: Hector Leonardo Aguila, Department of Immunology, University of Connecticut Health Center, 263 Farmington Ave., Farmington, Connecticut 06030, USA. Phone: (860) 679-7658; Fax: (860) 679-8130; E-mail: aguila@nso1.uchc.edu.

Find articles by Ai, Y. in: JCI | PubMed | Google Scholar

1Center for Vascular Biology and 2Department of Immunology, University of Connecticut Health Center, Farmington, Connecticut, USA. 3Department of Pathology, HUSLAB, and Haartman Institute, Helsinki University Central Hospital, and Genome-Scale Biology Research Program, University of Helsinki, Helsinki, Finland. 4Department of Pathology, Division of Diagnostics, University of Oulu, and Oulu University Hospital, Oulu, Finland. 5Janelia Farm Campus, Howard Hughes Medical Institute, Reston, Virginia, USA. 6Department of Molecular, Microbial, and Structural Biology, University of Connecticut Health Center, Farmington, Connecticut, USA. 7Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.

Address correspondence to: Timothy Hla, Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Box 69, 1300 York Avenue, New York, New York, USA. Phone: (212) 746-9953; Fax: (212) 746-2830; E-mail: tih2002@med.cornell.edu. Or to: Hector Leonardo Aguila, Department of Immunology, University of Connecticut Health Center, 263 Farmington Ave., Farmington, Connecticut 06030, USA. Phone: (860) 679-7658; Fax: (860) 679-8130; E-mail: aguila@nso1.uchc.edu.

Find articles by Wu, M. in: JCI | PubMed | Google Scholar

1Center for Vascular Biology and 2Department of Immunology, University of Connecticut Health Center, Farmington, Connecticut, USA. 3Department of Pathology, HUSLAB, and Haartman Institute, Helsinki University Central Hospital, and Genome-Scale Biology Research Program, University of Helsinki, Helsinki, Finland. 4Department of Pathology, Division of Diagnostics, University of Oulu, and Oulu University Hospital, Oulu, Finland. 5Janelia Farm Campus, Howard Hughes Medical Institute, Reston, Virginia, USA. 6Department of Molecular, Microbial, and Structural Biology, University of Connecticut Health Center, Farmington, Connecticut, USA. 7Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.

Address correspondence to: Timothy Hla, Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Box 69, 1300 York Avenue, New York, New York, USA. Phone: (212) 746-9953; Fax: (212) 746-2830; E-mail: tih2002@med.cornell.edu. Or to: Hector Leonardo Aguila, Department of Immunology, University of Connecticut Health Center, 263 Farmington Ave., Farmington, Connecticut 06030, USA. Phone: (860) 679-7658; Fax: (860) 679-8130; E-mail: aguila@nso1.uchc.edu.

Find articles by Hemmes, A. in: JCI | PubMed | Google Scholar

1Center for Vascular Biology and 2Department of Immunology, University of Connecticut Health Center, Farmington, Connecticut, USA. 3Department of Pathology, HUSLAB, and Haartman Institute, Helsinki University Central Hospital, and Genome-Scale Biology Research Program, University of Helsinki, Helsinki, Finland. 4Department of Pathology, Division of Diagnostics, University of Oulu, and Oulu University Hospital, Oulu, Finland. 5Janelia Farm Campus, Howard Hughes Medical Institute, Reston, Virginia, USA. 6Department of Molecular, Microbial, and Structural Biology, University of Connecticut Health Center, Farmington, Connecticut, USA. 7Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.

Address correspondence to: Timothy Hla, Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Box 69, 1300 York Avenue, New York, New York, USA. Phone: (212) 746-9953; Fax: (212) 746-2830; E-mail: tih2002@med.cornell.edu. Or to: Hector Leonardo Aguila, Department of Immunology, University of Connecticut Health Center, 263 Farmington Ave., Farmington, Connecticut 06030, USA. Phone: (860) 679-7658; Fax: (860) 679-8130; E-mail: aguila@nso1.uchc.edu.

Find articles by Ristimaki, A. in: JCI | PubMed | Google Scholar

1Center for Vascular Biology and 2Department of Immunology, University of Connecticut Health Center, Farmington, Connecticut, USA. 3Department of Pathology, HUSLAB, and Haartman Institute, Helsinki University Central Hospital, and Genome-Scale Biology Research Program, University of Helsinki, Helsinki, Finland. 4Department of Pathology, Division of Diagnostics, University of Oulu, and Oulu University Hospital, Oulu, Finland. 5Janelia Farm Campus, Howard Hughes Medical Institute, Reston, Virginia, USA. 6Department of Molecular, Microbial, and Structural Biology, University of Connecticut Health Center, Farmington, Connecticut, USA. 7Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.

Address correspondence to: Timothy Hla, Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Box 69, 1300 York Avenue, New York, New York, USA. Phone: (212) 746-9953; Fax: (212) 746-2830; E-mail: tih2002@med.cornell.edu. Or to: Hector Leonardo Aguila, Department of Immunology, University of Connecticut Health Center, 263 Farmington Ave., Farmington, Connecticut 06030, USA. Phone: (860) 679-7658; Fax: (860) 679-8130; E-mail: aguila@nso1.uchc.edu.

Find articles by Guo, C. in: JCI | PubMed | Google Scholar

1Center for Vascular Biology and 2Department of Immunology, University of Connecticut Health Center, Farmington, Connecticut, USA. 3Department of Pathology, HUSLAB, and Haartman Institute, Helsinki University Central Hospital, and Genome-Scale Biology Research Program, University of Helsinki, Helsinki, Finland. 4Department of Pathology, Division of Diagnostics, University of Oulu, and Oulu University Hospital, Oulu, Finland. 5Janelia Farm Campus, Howard Hughes Medical Institute, Reston, Virginia, USA. 6Department of Molecular, Microbial, and Structural Biology, University of Connecticut Health Center, Farmington, Connecticut, USA. 7Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.

Address correspondence to: Timothy Hla, Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Box 69, 1300 York Avenue, New York, New York, USA. Phone: (212) 746-9953; Fax: (212) 746-2830; E-mail: tih2002@med.cornell.edu. Or to: Hector Leonardo Aguila, Department of Immunology, University of Connecticut Health Center, 263 Farmington Ave., Farmington, Connecticut 06030, USA. Phone: (860) 679-7658; Fax: (860) 679-8130; E-mail: aguila@nso1.uchc.edu.

Find articles by Furneaux, H. in: JCI | PubMed | Google Scholar

1Center for Vascular Biology and 2Department of Immunology, University of Connecticut Health Center, Farmington, Connecticut, USA. 3Department of Pathology, HUSLAB, and Haartman Institute, Helsinki University Central Hospital, and Genome-Scale Biology Research Program, University of Helsinki, Helsinki, Finland. 4Department of Pathology, Division of Diagnostics, University of Oulu, and Oulu University Hospital, Oulu, Finland. 5Janelia Farm Campus, Howard Hughes Medical Institute, Reston, Virginia, USA. 6Department of Molecular, Microbial, and Structural Biology, University of Connecticut Health Center, Farmington, Connecticut, USA. 7Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.

Address correspondence to: Timothy Hla, Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Box 69, 1300 York Avenue, New York, New York, USA. Phone: (212) 746-9953; Fax: (212) 746-2830; E-mail: tih2002@med.cornell.edu. Or to: Hector Leonardo Aguila, Department of Immunology, University of Connecticut Health Center, 263 Farmington Ave., Farmington, Connecticut 06030, USA. Phone: (860) 679-7658; Fax: (860) 679-8130; E-mail: aguila@nso1.uchc.edu.

Find articles by Hla, T. in: JCI | PubMed | Google Scholar

Published November 2, 2009 - More info

Published in Volume 119, Issue 12 on December 1, 2009
J Clin Invest. 2009;119(12):3530–3543. https://doi.org/10.1172/JCI38263.
© 2009 The American Society for Clinical Investigation
Published November 2, 2009 - Version history
Received: December 8, 2008; Accepted: August 26, 2009
View PDF
Abstract

The RNA-binding protein HuR (also known as ELAV1) binds to the 3′-untranslated region of mRNAs and regulates transcript stability and translation. However, the in vivo functions of HuR are not well understood. Here, we report that murine HuR is essential for life; postnatal global deletion of Elavl1 induced atrophy of hematopoietic organs, extensive loss of intestinal villi, obstructive enterocolitis, and lethality within 10 days. Upon Elavl1 deletion, progenitor cells in the BM, thymus, and intestine underwent apoptosis, whereas quiescent stem cells and differentiated cells were unaffected. The survival defect of hematopoietic progenitor cells was cell intrinsic, as transplant of Elavl1–/– BM led to compromised hematopoietic reconstitution but did not cause lethality. Expression of p53 and its downstream effectors critical for cell death were induced in progenitor cells as HuR levels declined. In mouse embryonic fibroblasts, HuR bound to and stabilized the mRNA for Mdm2, a critical negative regulator of p53. Furthermore, cell survival was restored by expression of Mdm2 in Elavl1–/– cells, suggesting that HuR keeps p53 levels in check in progenitor cells and thereby promotes cell survival. This regulation of cell stress response by HuR in progenitor cells, which we believe to be novel, could potentially be exploited in cytotoxic anticancer therapies as well as stem cell transplant therapy.

Introduction

In eukaryotes, once mRNA precursors are transcribed, splicing, transport, translation, and degradation are carefully regulated to achieve precise spatial, temporal, and tissue-specific control of gene expression (1, 2). The significance of such mechanisms, collectively known as posttranscriptional RNA regulation, in physiology and pathology is just beginning to be appreciated. Current data support a model whereby specific RNA-binding proteins and small RNAs (such as microRNA [miRNA]) interact with noncoding, regulatory regions of mRNAs and determine the fate of a given transcript (3, 4).

HuR (also known as ELAV1), a member of the ELAV (embryonic lethal abnormal vision) RNA-binding protein family, plays an important role in AU-rich element–mediated (ARE-mediated) mRNA stability and translation (5–7). HuR function is closely tied to its translocation from the nucleus into the cytoplasm, in which it modulates transcript stability and translation.

In vitro studies have shown that HuR regulates expression of genes involved in key cellular processes, such as tumorigenesis, hypoxic gene regulation, cell-cycle control, inflammation, cell stress response, and apoptosis (5–9). Indeed, HuR promotes survival of cells and positively regulates the expression of antiapoptotic proteins and suppresses proapoptotic proteins (10–12). Enhanced HuR expression is correlated with cancer progression (13–15), thus serving as a prognostic biomarker for adenocarcinoma.

In contrast, in vivo function of HuR is not clear, as only limited number of studies have examined the function of this RNA-binding protein in animal models. When HuR was overexpressed in the myeloid lineage in a transgenic mouse model, it induced translational silencing of the ARE-containing transcripts, such as TNF-α, even though the mRNAs were stabilized (16). Global overexpression of HuR in transgenic mice led to impairment of male gametogenesis, suggesting a role of HuR in germ cell function (17). A recent study published during the review of this manuscript reported the essential role of HuR in mouse embryogenesis. Elavl1 null mice exhibited embryonic lethality due to defects in placental development. In addition, defects in spleen and bone development were also observed, suggesting the complex role of HuR in embryonic development (18).

With the aim of understanding the in vivo function of HuR, we developed a mouse model in which the Elavl1 gene can be deleted by tamoxifen-inducible Cre recombinase–mediated gene excision. We report for what we believe to be the first time the essential role of posttranscriptional regulator HuR in the survival of progenitor cell populations in hematopoietic and intestinal systems. We also describe a HuR-regulated mechanism in progenitor cells that keeps p53 protein levels in check. These data underscore the essential role of posttranscriptional gene regulatory mechanisms in progenitor cell fate in vivo.

Results

Essential postnatal role of HuR. The schematic of the Elavl1f/f construct in which the Elavl1 gene can be deleted by Cre-Lox–mediated gene excision is shown in Figure 1A. We crossed Elavl1f/+ mice with Hprt-Cre mice (19), which yielded Elavl1+/– mice. Intercrosses of F1 generation and analysis of approximately 300 F2 mice yielded Elavl1+/– and Elavl1+/+ mice in the ratio of 2:1. However, no live-born Elavl1–/– mice were derived, indicating that Elavl1 is required for normal embryonic development. Elavl1+/– mice appeared healthy and were able to reproduce.

Deletion of Elavl1 in adult mice leads to lethality.Figure 1

Deletion of Elavl1 in adult mice leads to lethality. (A) Tamoxifen-induced Elavl1 disruption in Elavl1f/f/Rosa26Cre/ERT2 (Elavl1Δ/Δ) mice. A schematic representation of conditional Elavl1 gene locus is shown. Arrows indicate the position of PCR primers; open triangles indicate loxP sites; the filled triangle indicates Frt site; and filled boxes indicate exons. F1, forward 1; R1, reverse 1. (B) PCR analysis of genomic DNA from indicated organs of mice 4 days after tamoxifen administration indicates either floxed or Elavl1 deletion (Δ) or cre bands. SI, small intestine. (C) IB analysis of tissue extracts with HuR antibody from Elavl1f/f and Elavl1Δ/Δ mice, 3 days after tamoxifen treatment. The same blot was reprobed with a β-actin mouse mAb. S, spleen; T, thymus; C, colon; J, jejunum; I, ileum. (D) Weight loss monitored over a period of 10 days upon deletion of Elavl1. (n = 4; *P < 0.05). (E) Cachexic phenotype of Elavl1Δ/Δ mice observed 4 days after tamoxifen administration. (F) Kaplan-Meier survival curves of Elavl1f/f [n = 8] and Elavl1Δ/Δ [n = 10] mice after tamoxifen treatment (P < 0.01, Log-rank test). Arrows indicate 3 doses of tamoxifen administration in D and F.

We then proceeded to determine the postnatal function of HuR by tamoxifen-inducible Cre (Rosa26Cre/ERT2) recombinase-mediated gene deletion (20). Elavl1f/fRosa26Cre/ERT2 mice (8 weeks old) were administered tamoxifen (by oral administration for 3 consecutive days), and the extent of deletion of the Elavl1 gene was determined by PCR of genomic DNA (the resulting mouse strain is referred to as Elavl1Δ/Δ). Analysis at 4 days showed that the Elavl1 gene was deleted efficiently by tamoxifen administration (Figure 1B), with concomitant reduction of HuR polypeptide expression in intestinal and hematopoietic tissues (Figure 1C). After tamoxifen administration, Elavl1Δ/Δ mice exhibited signs of cachexia and eventually died within 10 days, whereas the Elavl1f/f mice were unaffected (Figure 1, D–F). These data indicate that HuR function is essential for postnatal life.

Lack of HuR leads to hematopoietic and immune defects. Rapid and dramatic atrophy of immune and hematopoietic organs were observed upon Elavl1 deletion (Figure 2A). Histological sections indicate marked decrease in cellularity, with disappearance of follicles in these organs. In the BM sections, decreased cellularity of immature cells was observed (Figure 2B). Total cell numbers in BM, thymus (Figure 2C), spleen, and LN (data not shown) declined rapidly, suggesting a profound effect on hematopoiesis. In blood, leukocyte counts declined by approximately 65% within 4 days. In contrast, granulocyte counts were slightly increased, approximately 2 fold, while platelets and red blood cell numbers remained the same (Supplemental Figure 1; supplemental material available online with this article; doi: 10.1172/JCI38263DS1), suggesting that HuR function may be more critical in actively proliferating cells.

Requirement of HuR for postnatal hematopoiesis.Figure 2

Requirement of HuR for postnatal hematopoiesis. (A) Atrophy of spleen, thymus, and LN (L) 4 days after deletion of Elavl1. (B) H&E stain of tissue sections from Elavl1f/f or Elavl1Δ/Δ mice 4 days after tamoxifen treatment. Original magnification, ×5 (spleen, thymus, and LN); ×40 (BM). Scale bar: 50 μm (spleen, thymus, and LN); 20 μm (bone). B, BM. (C) Elavl1f/f and Elavl1Δ/Δ mice were treated with tamoxifen, and the total number of BM cells and thymocytes were counted at indicated times (*P < 0.05; n = 5).

To define the cellular changes in the hematopoietic lineages, we performed a detailed flow cytometric analysis of cells from Elavl1f/f and Elavl1Δ/Δ mice. For the BM, we evaluated the presence of HSCs (21, 22), common lymphoid progenitors (CLPs) (23), total B cells, immature B cells, mature B cells (24), myeloid cells and their progenitors (25, 26), and erythroid progenitors (27) (Figure 3, A and B). These results showed an overall maintenance of HSCs, decreased numbers of CLPs, B cell progenitors, myeloid cells and their progenitors, and erythroid progenitors. Mature populations were not affected, indicating that progenitor cells are selectively targeted. This was validated by ex vivo hematopoiesis assays in methylcellulose (Figure 3C), showing a decreased number of myeloerythroid colonies in BM from the HuR-depleted animals.

Effect of HuR loss on hematopoietic cells.Figure 3

Effect of HuR loss on hematopoietic cells. (A) A schematic of hematopoietic cell lineage and their markers (CMP, common myeloid progenitor; DN, double negative; DP, double positive). Cells that were affected by loss of Elavl1 are shaded. (B) Distribution of HSCs (Lin–CD117+Sca-1+), CLPs (Lin–CD117+IL-7Rα+), total B cells (B220/CD45R+CD19+), immature B cells (CD19+B220+IgM–CD117+), mature B cells (B220+IgM+), myeloid cells (CD11b+), monocytes/macrophages (CD11b+CD115+), and erythroid progenitors (Ter119+, CD117+) in BM. Cells were quantified by multiparameter flow cytometry and were analyzed 4 days after tamoxifen administration of Elavl1f/f and Elavl1Δ/Δ mice (*P < 0.05, **P < 0.01; n = 4). (C) Methylcellulose CFC assay of total BM cells isolated from Elavl1f/f and Elavl1Δ/Δ mice, 4 days after tamoxifen treatment, and grown for 11 days in vitro (*P < 0.05; n = 4).

To determine the effect of HuR on T cell lineage, we evaluated the distribution of cells in different stages of thymocyte development (Figure 3B) (28). Results show selective depletion of double-positive T cells, which are known to be rapidly proliferating (Figure 3B). However, single-positive (CD4+ and CD8+) and double-negative (CD4– and CD8–) populations showed an increase in percentage cellularity due to decreased cell numbers (Figure 2C).

Regulation of hematopoietic progenitor cell survival and proliferation by HuR. To understand the underlying cause of decreased cellularity, we measured apoptosis and necrosis by flow cytometry (29). Analysis of BM cells showed increased apoptotic and necrotic cells in the B progenitor population (Figure 4, A and B). In contrast, mature B cells did not exhibit increased cell death upon the deletion of Elavl1. Interestingly, BrdU incorporation was also significantly attenuated in the B cell population (Figure 4C). Immunohistochemistry with BrdU antibody confirmed these results (Supplemental Figure 2). In thymus, increased apoptosis and necrosis and decreased BrdU incorporation in the double-positive T progenitor (CD4+CD8+) population (Figure 4, D–F) was observed upon Elavl1 deletion. These data strongly suggest that HuR is required for the survival of progenitor cells in the BM and the thymus.

Regulation of immune and hematopoietic progenitor cell survival and prolifeFigure 4

Regulation of immune and hematopoietic progenitor cell survival and proliferation by HuR. (A and B) BM cells from Elavl1f/f and Elavl1Δ/Δmice were analyzed by flow cytometry to detect B cell progenitors (CD19+CD45R/B220hiIgM–CD117+) and mature B cells (CD19+CD45R/B220hiIgM+CD117+) that are undergoing apoptosis (A) and necrosis (B) 48 hours after tamoxifen treatment (*P < 0.05; n = 3). (C) BrdU incorporation into B cells (B220+IgM–) was detected by flow cytometry 48 hours after tamoxifen treatment (*P < 0.05; n = 3). (D) Thymocytes from Elavl1f/f and Elavl1Δ/Δ mice were analyzed by flow cytometry to detect double-positive T progenitors (CD4+CD8+) that are undergoing apoptosis (E), necrosis (F), and proliferation 48 hours after tamoxifen treatment (*P < 0.05; n = 3). (G) HuR expression in BM-derived hematopoietic cell populations sorted by FACS was detected by immunofluorescence confocal microscopy. HuR (green); nucleus (blue). Original magnification, ×63. Scale bar: 5 μm. (H) Elavl1 mRNA expression and (I) percentage of BrdU-positive cells in BM-derived hematopoietic cell populations sorted by FACS isolated from Elavl1f/f and Elavl1Δ/Δ mice 48 hours after tamoxifen treatment by q-RT-PCR. (*P < 0.05; n = 3). Ro indicates mRNA levels.

Next, HuR expression during early hematopoiesis and B cell development was determined by immunofluorescence analysis of FACS-sorted BM-derived cells. Low HuR staining was detected in the cytoplasm and nucleus of quiescent long-term HSC (LT-HSC) population (Lin–Sca-1+c-kit+Flt3–) (Figure 4G) (30). In the short-term HSC (ST-HSC) population (Lin–Sca-1+c-kit+Flt3+), which included early progenitors, strong HuR staining was seen in more than 90% of cells. Interestingly, HuR staining in this population highlights punctate structures in the nucleus. In the CLP population (Lin–Sca-1+c-kit+IL-7R+), a similar pattern of HuR expression was seen; however, cells expressing lower levels of HuR were also observed. In the immature B cell population (CD45R+IgM–), only 30% of the cells expressed HuR in the cytoplasm. In the mature B cell population, primarily cytoplasmic localization was seen in approximately 20% of the cells.

The specificity of Cre-mediated Elavl1 gene deletion in different cell populations was tested by analyzing FACS-sorted cells. As shown in Figure 4H, Elavl1 mRNA expression is markedly reduced in both HSC and early lymphoid progenitor (ELP) populations. BrdU+ cells are prominent in the ELP population and drastically reduced by Elavl1 gene deletion (Figure 4I). Cell-cycle analysis of the sorted progenitor population indicated that Elavl1 gene deletion did not influence the cell-cycle parameters (Supplemental Figure 3), suggesting that the primary effect of HuR loss is the induction of apoptosis.

HuR maintains intestinal integrity by preventing epithelial progenitor cell apoptosis. Because the hematopoietic and immune deficiency alone is unlikely to be the main cause of lethality in the time frame of the experiment (<10 days), we examined other organ systems after Elavl1 deletion. The gastrointestinal (GI) tract exhibited marked abnormality within 2–4 days of Elavl1 deletion. As shown in Figure 5A, the stomach was distended and the proximal intestine was devoid of food, suggesting intestinal blockage. In contrast to the GI tract, gross morphology and histological sections of skin, heart, liver, kidney, lung, and mammary gland appeared normal, even though effective reduction in HuR polypeptide was seen in these tissues (Supplemental Figure 4). Moreover, induction of vascular collapse and hypoxia in the affected tissues were ruled out, because hypoxia-inducible factor–1α expression was not induced after HuR deletion (Supplemental Figure 5). Histological analysis of the small intestine (Figure 5B) indicated extensive villus atrophy and disruption of the epithelial architecture within 2–3 days following gene deletion. In the colon, epithelial disruption at the mucosal layer and goblet cell loss were observed. These observations suggest that HuR function is essential for intestinal turnover and/or homeostasis.

Role of HuR in intestinal integrity and progenitor cell survival.Figure 5

Role of HuR in intestinal integrity and progenitor cell survival. (A) Abnormal appearance of the GI tract 4 days after deletion of Elavl1. Note the distended stomach and thin-walled intestinal tract devoid of food. (B) H&E stain of intestinal tissue sections from Elavl1f/f and Elavl1Δ/Δ mice 4 days after tamoxifen administration. Note the effect of Elavl1 deletion on villus atrophy, epithelial cell disruption in the small intestine, and loss of tissue architecture and goblet cells in the colon. D, duodenum. Original magnification, ×20. Scale bar: 50 μm. (C) Immunohistochemical staining of small intestinal tissue sections from Elavl1f/f and Elavl1Δ/Δ mice 48 hours after tamoxifen treatment with either HuR or Ki67 antibody or TUNEL stain. Note that although HuR is primarily expressed in the epithelial cells, some stromal cells in the lamina propria also show immunoreactivity. Original magnification, ×20. Scale bar: 50 μm. (D) Immunohistochemical staining of colon sections from Elavl1f/f and Elavl1Δ/Δ mice 48 hours after tamoxifen treatment with either H&E stain, TUNEL, or Ki67 stain. Original magnification, ×400 (first and third rows); ×600 (second and fourth rows). (E) IB analysis of E-cadherin and β-catenin expression in intestinal tissue extracts isolated from Elavl1Δ/Δ mice upon tamoxifen treatment. (F) Immunohistochemical staining of F4/80 (myeloid marker) in small intestinal tissue sections from Elavl1f/f and Elavl1Δ/Δ mice 48 hours after tamoxifen treatment. Note that an intact villus was chosen to highlight the lamina propria and the epithelial compartments. Original magnification, ×20. Scale bar: 50 μm.

In the small intestine, HuR is expressed in both epithelial and stromal compartments (Figure 5C). Nuclear HuR was detected strongly in the proliferating progenitors in the crypts, mature epithelial cells, and few stromal cells in the lamina propria. HuR expression was weaker in the terminally differentiated epithelial cells in the tip of the villus. When Elavl1 gene was deleted by tamoxifen administration, proliferation of progenitor cells in the crypts decreased (Figure 5C). In addition, TUNEL staining indicated significant increase in apoptotic cells (WT, 0.5%; KO, 14.3%, n = 3; P = 0.015; Figure 5C). Likewise, in the colon (Figure 5D), apoptosis of cells in the lamina propria was increased upon the deletion of Elavl1 (WT, 12.12 ± 3.32, n = 2; KO, 42.88 ± 8.45, n = 8; P = 0.0019). Epithelial cell apoptosis was also observed (WT, 1.38 ± 0.53, n = 3; KO, 4.88 ± 0.79, n = 8; P = 0.0030). Furthermore, lack of HuR suppressed β-catenin and E-cadherin expression in the intestinal epithelium, suggesting that HuR expression may be required to maintain the expression of key regulatory proteins required for the integrity of the epithelial layer (Figure 5E). Staining of the pan-macrophage marker F4/80 was not significantly altered after Elavl1 deletion (Figure 5F). These data suggest that HuR is required for proliferation and integrity of the intestinal epithelial progenitor cells.

Increased sensitivity to irradiation in Elavl1+/– mice. Since the phenotype of the Elavl1 KO mice appears to resemble various aspects of lethal radiation syndrome, such as BM suppression and intestinal injury, we asked whether loss of an allele of Elavl1 leads to increased sensitivity to radiation injury. Nonirradiated Elavl1+/– mice had slightly reduced number of hematopoietic cells in BM and spleen compared with the Elavl1+/+ mice (Figure 6, B and C). When the mice were subjected to whole-body gamma irradiation (9 Gy, which is sufficient to induce BM suppression but not intestinal injury), the decrease in cellularity in the BM, spleen, and thymus of Elavl1+/– mice was much more drastic (Figure 6, A, C, and D). Tamoxifen treatment of Elav1wt/wtRosaCreERT2 mice did not result in loss of cellularity in BM and thymus, which ruled out Cre-mediated toxicity (Supplemental Figure 6). Thus, HuR protects progenitor cells from gamma irradiation–induced cell death.

Elavl1+/– mice have increased sensitivity to whole-body irradiation.Figure 6

Elavl1+/– mice have increased sensitivity to whole-body irradiation. (A) A schematic of Elavl1+/+ and Elavl1+/– mice exposed to radiation. (B) Total cell number in BM, spleen, and thymus in nonirradiated Elavl1+/+ and Elavl1+/– mice (n = 3). (C) H&E stain of bone and spleen tissue sections from Elavl1+/+ and Elavl1+/– mice before and after irradiation. Original magnification, ×10 (spleen); ×40 (BM). Scale bar: 20 μm (BM); 100 μm (spleen). (D) Total number of cells isolated from BM, spleen, and thymus of irradiated Elavl1+/+ and Elavl1+/– mice (n ≥ 5). Horizontal bars indicate mean of data points, and each dot represents an analyzed mouse (B and D).

BM transplantation studies suggest the cell-intrinsic function of HuR. To determine whether the hematopoietic progenitor cell phenotype in the Elavl1Δ/Δ mice is cell intrinsic, we conducted BM transplantation studies. Irradiated CD45.1 congenic recipients received BM cells from either Elavl1f/f or Elavl1f/fRosa26CreERT2 mice. At 10 weeks after transplantation, mice were treated with tamoxifen to delete Elavl1 in the hematopoietic compartment and were monitored over a period of 16 days. Interestingly, all of the recipient mice survived during the experimental time frame and did not exhibit symptoms of cachexia or weight loss, despite the fact that Elavl1 was efficiently deleted in the BM and the thymus (Figure 7B). Intestinal tissues of these chimeras appear normal (Figure 7C), suggesting that the effect of Elavl1 deletion on hematopoietic progenitor cells is cell intrinsic.

Cell-intrinsic effect of HuR.Figure 7

Cell-intrinsic effect of HuR. (A) A schematic of BM transplant. (B) PCR analysis of genomic DNA from indicated organs of mice 3 days after tamoxifen administration. (C) H&E stain of small intestinal tissue sections from Elavl1f/f and Elavl1Δ/Δ chimera at day 16. Original magnification, ×20. Scale bar: 50 μm. (D–F) Isolated cells from BM (D and F) and thymus (E) were analyzed by FACS as described. Cell numbers of different lineages and differentiation stages are plotted (n = 5, *P < 0.01). (G) Total BM cells and thymocytes isolated from Elavl1f/f and Elavl1Δ/Δ chimera on day 16 are shown (n = 5; *P < 0.01).

The immune organs were analyzed by FACS analysis 16 days after Elavl1 deletion. Total BM and thymocyte counts declined drastically in the mice with Elav1-deleted BM (Figure 7G). B progenitors and pro-B and immature B cell numbers were strongly reduced whereas mature B cells were not (Figure 7D). Likewise in the thymus, the double-positive population was significantly reduced (Figure 7E), whereas the CD4+ and CD8+ populations did not change. The apparent increase in the double-negative population is due to the loss of total cell numbers. In the myeloid cells of the BM, there was substantial decrease in total monocytes, whereas neutrophils were not significantly affected (Figure 7F). Interestingly, HuR expression is higher in monocytes than in polymorphonuclear leukocytes (PMNs) isolated from peritoneal exudates induced by thioglycollate elicitation (Supplemental Figure 7).

Loss of Elavl1 affects genes involved in hematopoiesis, apoptosis, and proliferation in BM. Given that HuR is a RNA-binding protein involved in posttranscriptional regulation, we searched for the gene expression changes in progenitor cells upon HuR loss. We conducted a microarray analysis of total RNA from BM of Elavl1f/f and Elavl1Δ/Δ mice 24–48 hours after treatment with tamoxifen, which is the time frame before the occurrence of maximal cell death. As expected, the Elavl1 transcript was downregulated in BM cells of Elavl1Δ/Δ mice (60%–90% within 24–48 hours; Figure 8B).

Microarray analysis of the transcript expression pattern in BM upon loss ofFigure 8

Microarray analysis of the transcript expression pattern in BM upon loss of HuR. (A) Ingenuity pathway analysis (31) was used to classify the transcriptome changes that occur in BM after Elavl1 deletion. (B–D) Changes in specific genes involved in hematopoiesis (B), apoptosis (C), and cell-cycle control (D) after Elavl1 deletion. Graphs represent Elavl1Δ/Δ/Elavl1f/f; n = 3; (transcripts shown have P < 0.001; for downregulated transcripts, x axis represents –1/x-fold change in gene expression).

Microarray data was analyzed by the Ingenuity pathway analysis (31). Of the 6,790 transcripts that exhibited significant changes (P < 0.001), genes classified to regulate cell death, cellular growth and differentiation, cell cycle, and organismal survival were most prominent (Figure 8A).

Hematopoietic transcription factors (Klf1, Tal1, Zfpm1, Gata1) were downregulated. In contrast, early HSC markers (Nanog, Sox2, Musashi [Msi1h and Msi2h]) were induced. This is consistent with loss of progenitors in multiple lineages (CLP, ELP, common myeloid progenitor), the resultant decline in differentiated cells, and a slight increase in HSCs. Regulators of apoptosis were altered by HuR loss. For example, survival factors (Bcl2, Bcl-XL, survivin) were downregulated, whereas apoptotic inducers (c-Myc, caspase-9, caspase-8–associated protein-2, NOXA, PUMA) were upregulated. Among the cell-cycle regulator transcripts, we noticed a reduction in cyclin E, proliferating cell nuclear antigen (PCNA), and the Ki67 antigen (MKi67). However, we also noticed an increase in the expression of mRNA for cyclin G1 (Ccng1), a target of the tumor suppressor p53. Interestingly, the G1/S cell-cycle regulator p21Cip1/Waf1, a major p53-regulated inhibitor of cyclin-dependent kinases (32), was also induced. Indeed, several genes in the p53 pathway were regulated by HuR loss. For example, cell-cycle regulators (Pcna, Rb1, 14-3-3σ [Sfn]), cell survival factors (Bcl2), apoptotic inducers (DR4 [Apo2], TRAILR-1 [Tnfrsf10A], Noxa, PUMA), regulators of cell-cycle arrest (p21Cip1/Waf1, Atm) as well as the p53 mRNA itself were induced upon the deletion of Elavl1 (Figure 8, B–D, and Supplemental Table 1), suggesting the involvement of the p53 pathway.

Loss of Elavl1 leads to p53 induction in hematopoietic and intestinal progenitor cell compartments. To determine whether the p53 pathway is induced in a differentiation-specific manner in the BM cells, we examined the expression of p53, its upstream regulator Mdm-2, and the downstream gene p21Cip1/Waf1 (32) in sorted BM populations (Figure 9A). The induction of the p53 mRNA was observed in both the quiescent HSCs as well as the proliferating ELP populations. This was correlated with the reduction in Mdm-2 expression in both HSC and ELP populations, suggesting that loss of Mdm-2 led to the induction of p53. Interestingly, p21Cip1/Waf1 was induced strongly only in the ELP population, whereas c-myc, an important proapoptotic factor, was induced in both HSC and ELP populations.

Induction of the p53 pathway in hematopoietic and intestinal progenitors wiFigure 9

Induction of the p53 pathway in hematopoietic and intestinal progenitors with loss of HuR. (A) Total BM cells isolated from Elavl1f/f and Elavl1Δ/Δ mice (n = 3) 48 hours after tamoxifen treatment were pooled and sorted by FACS to obtain HSCs and ELPs. Total RNA was isolated, and gene expression for p53, p21Cip1/Waf1, Mdm2, and c-myc mRNA levels was determined by q-RT-PCR (*P < 0.05). (B) IB analysis of BM extracts from Elavl1Δ/Δ mice treated with tamoxifen for the indicated time interval. (C) Immunohistochemical staining of intestinal crypts from Elavl1f/f and Elavl1Δ/Δ mice at 48 hours after tamoxifen administration. Original magnification, ×40. Scale bar: 10 μm. (D) IB analysis of tissue extracts isolated from Elavl1f/f and Elavl1Δ/Δ mice after tamoxifen treatment.

IB analysis of BM extracts from Elavl1Δ/Δ mice indicated that p53, p21Cip1/Waf1, Bax, p19ARF, and c-myc levels were induced as HuR levels declined (Figure 9B). Phospho-CHK2 was induced, whereas Mdm-2 and Bcl-2 levels declined. These data are consistent with the induction of p53-dependent apoptotic response.

In the intestine, the deletion of Elavl1 and induction of p53 and its downstream targets, PUMA and p21Cip1/Waf1, were observed in progenitor cells of the crypts (Figure 9C). Expression of Musashi, a marker for early intestinal stem cells (33) was not reduced, suggesting that early intestinal stem cells do not undergo apoptosis upon Elavl1 deletion. In contrast, proliferation (Ki67 positivity) was dramatically reduced and TUNEL positivity was induced in small intestinal crypts, suggesting that progenitors (also known as transit amplifying cells) undergo cell-cycle arrest and apoptosis upon HuR loss. p53 and its downstream target p21Cip1/Waf1 were induced specifically in the intestine but not in lung and liver of Elavl1Δ/Δ mice (Figure 9D), suggesting that HuR regulation of the p53 pathway is specific for progenitor cells.

HuR binds to Mdm-2 and regulates p53 levels in vitro. Next, we examined the effect of HuR loss on mouse embryonic fibroblasts (MEFs) derived from Elavl1f/f and Elavl1f/fRosa26CreERT2 mice. The 4-hydroxytamoxifen (4HT) treatment suppressed HuR expression and cell proliferation, while inducing p53 and p21Cip1/Waf1 expression (Figure 10, A and B). Mdm-2 was downregulated at early time points, while p19ARF, an inhibitor of Mdm-2 function, was induced. Loss of Mdm-2 expression and the inhibition of its activity by p19ARF may be responsible for the induction of p53 in MEFs. Interestingly, c-myc, which activates p19ARF (34), was substantially upregulated in a time-dependent manner. Furthermore, phosphorylation of CHK2, a check point kinase that is known to activate p53 activity upon DNA damage (32), was induced, suggesting that HuR loss induces cell stress response. However, CHK2 protein level was not altered, suggesting that it is activated by an upstream kinase. Indeed, ATM, a DNA damage-inducible kinase, was strongly induced in the BM upon HuR loss (Figure 8D).

Binding and regulation of Mdm-2 by HuR in MEFs.Figure 10

Binding and regulation of Mdm-2 by HuR in MEFs. (A) Growth curve and (B) IB analysis of MEF cells isolated from Elavl1f/f and Elavl1f/f/RosaCre mice treated with different doses of 4HT for the indicated time periods (*P < 0.05; n = 3). For IB analysis, MEFs treated with 2.5 μM of 4HT are shown. (C) Ribonucleoprotein (RNP) complexes were immunoprecipitated from MEFs, using different doses of HuR-specific antibody or mouse IgG, and immunoprecipitated RNA was purified and analyzed for the level of Mdm2 transcript by q-RT-PCR. (*P < 0.05; n = 2). (D) Percentage of Mdm2 mRNA remaining was determined in Elavl1f/f and Elavl1Δ/Δ MEFs upon addition of Actinomycin D for the indicated time interval (n = 2). (E) IB analysis of Mdm-2 overexpression in MEFs transfected with pCMV6-Mdm-2 cDNA. (F) Growth curve analysis of Elavl1f/f/cre MEFs transfected with pCMV6-Mdm-2 or pCMV6 alone, in presence of 4HT or vehicle (ethanol, ETOH) for the indicated time intervals (*P < 0.05; n = 3).

Mdm2 mRNA and protein levels were rapidly downregulated upon HuR loss, suggesting that HuR may directly regulate the expression of Mdm-2 at the posttranscriptional level. Indeed, the 3′-untranslated region of the Mdm2 mRNA is AU rich and contains several copies of AREs and canonical HuR-binding motifs (Supplemental Figure 9). We tested whether HuR binds to Mdm2 mRNA by immunoprecipitating MEF cell extracts with anti-HuR or control IgG and analyzing the presence of Mdm2 transcript by quantitative real-time PCR (q-RT-PCR). As shown in Figure 10C, Mdm2 mRNA was recovered from HuR immunoprecipitates in a dose-dependent manner. In addition, loss of HuR led to reduction in Mdm2 mRNA half-life from 1.3 to 0.8 hours, suggesting that HuR regulates the stability of Mdm2 mRNA (Figure 10D). To determine whether regulation of Mdm-2/p53 pathway is essential for cell death, we treated MEFs with 4HT, followed by transfection with Mdm-2 expression plasmid (Figure 10E), and quantified cell proliferation. Indeed Mdm-2 overexpression rescued suppression of cell proliferation induced by HuR loss (Figure 10F).

Discussion

Several RNA-binding proteins that interact with the AREs in the 3′-untranslated region of transcripts have been characterized in vitro and in vivo (35, 36). These proteins regulate RNA stability, transport, and translation. HuR is unique in that it stabilizes the transcripts involved in inflammation such as cyclooxygenase-2 and tumor necrosis factor-α (8, 9, 36, 37). However, its function is not limited to the regulation of genes involved in the inflammatory response (5, 7, 38). Indeed, recent studies suggest that HuR may regulate gene expression by modulating the activity of miRNAs (4, 39).

The interaction of HuR with transcripts involved in various cellular processes suggests its multifunctionality. Indeed, HuR function has been implicated in numerous biological processes including cell proliferation, survival, angiogenesis and cancer in addition to the aforementioned function in inflammation (5, 7, 38). However, in vivo functions of HuR are not well understood, especially in the postnatal period. A recent paper described the embryonic lethal phenotype of Elav1–/– mice and suggested that HuR regulates placental development (18). Thus, although an essential role of HuR in embryonic development was described, its function in the adult organisms is not understood.

Our inducible global gene deletion model indicated that HuR plays a fundamental role in normal organismal survival and homeostasis. As HuR levels declined, rapidly proliferating tissues were affected first. Indeed, tissues with high cell proliferation and turnover express the highest levels of HuR in vivo. Thus HuR may be upregulated during periods of active cell proliferation, in which it plays an essential role in cell survival and is downregulated in more differentiated cells. Indeed, expression and subcellular localization of HuR shows a dynamic pattern during hematopoiesis. Our study, however, did not examine the functions of HuR in differentiated cells. The mouse model we developed will be useful in this purpose for delineating the tissue specific function of HuR.

The effect of HuR loss in hematopoietic and intestinal systems is profound and rivals lethal radiation exposure. This underscores the importance of posttranscriptional gene regulatory mechanisms in progenitor cells during periods of rapid cell expansion. At the cellular level, HuR function is needed for cell survival; lack of HuR led to rapid induction of apoptosis. Differentiated cells and quiescent stem cells do not require HuR for survival. BM transplantation studies indicate that the requirement for HuR in progenitor cell phenotype is cell intrinsic and not driven by generalized organismal demise.

Microarray studies in BM cells indicated that gene expression changes accompanied cellular alterations. For example, regulators of hematopoiesis were downregulated, cell-cycle promoters were suppressed and inhibitors induced, and apoptotic inducers were increased. Interestingly, the p53 pathway was induced as HuR levels declined. Moreover, we uncovered what we believe to be a novel regulation of Mdm-2, an important E3 ubiquitin ligase for p53. HuR binds and stabilizes the Mdm2 mRNA. Indeed, Mdm-2 expression was rapidly downregulated in progenitor cells as HuR levels declined. Interestingly, c-myc, which is repressed by HuR through recruitment of the miRNA let-7 (39) was strongly induced in cells that lack HuR. It is known that c-myc activates p19ARF (34). Thus, combined effects of Mdm-2 expression and the inhibition of its activity by p19ARF may be responsible for the strong induction of p53. Interestingly, CHK2 phosphorylation and ATM induction were seen, suggesting the activation of the cell stress response pathway in the absence of HuR. The ability of Mdm-2 expression to restore cell proliferation in MEFs that lack HuR strongly suggests that activation of the p53 pathway is essential in the progenitor cell apoptosis phenotype. These data imply that HuR regulated posttranscriptional mechanisms are required to keep p53 levels in check in proliferating progenitor cells.

In conclusion, our studies uncovered what we believe to be a novel posttranscriptional gene regulatory system in progenitor cells that requires HuR to regulate p53 expression. Since the HuR loss in this inducible gene deletion animal model phenocopies the radiation syndrome, HuR regulation of cell stress response in progenitor cells may be exploited in cancer therapy. For example, inhibition of HuR expression or function in cancer stem/progenitor cells may lead to rapid apoptosis and tumor shrinkage. In addition, preservation of HuR expression in normal cells may minimize the side effects of cytotoxic anticancer therapies, such as pancytopenia and radiation syndrome. As a corollary, increased HuR function in progenitor cells may enhance the efficacy of stem cell transplant therapy. Further studies should examine the role of HuR in embryonic and inducible pluripotent stem cells.

Methods

Mice. Animal procedures were approved by the Institutional Animal Care and Use Committee of the University of Connecticut Health Center. Tail DNA samples were used for PCR to monitor the deletion of HuR exons 2–6 and the presence of the Cre allele. Rosa26Cre/ERT2 mice were provided by G.-H. Fong (University of Connecticut Health Center; ref. 20). Tamoxifen (Sigma-Aldrich) was administered to 6- to 8-week-old Elavl1f/f and Elavl1f/fRosa26Cre/ERT2 mice by gavage at the dose of 200 mg/kg in corn oil. In most experiments, tamoxifen was given daily for 3 consecutive days.

Mice were injected with 200 μl BrdU solution (5 mg/ml) (Sigma-Aldrich) in PBS intraperitoneally for 4 hours, and the tissues were harvested for immunohistochemistry with the anti-BrdU antibody. Survival curves were generated using the Kaplan-Meier method, and significance was evaluated using the log-rank test.

Immunohistochemistry. Immunohistochemical staining was conducted in paraffin-embedded sections, according to the manufacturer’s instructions, with the following antibodies: biotinylated HuR monoclonal antibody (1:200) (5), rat monoclonal Ki67 (1:200, Dako), mouse monoclonal p53 (1:150, Santa Cruz Biotechnology Inc.), rabbit polyclonal PUMA (1:200, Cell Signaling Technology), and IgG with a Vectastain ABC kit (Vector Laboratories).

TUNEL staining was performed using an ApopTag Peroxidase In Situ Apoptosis Detection Kit (Chemicon International) according to manufacturer’s instructions. The apoptotic index was scored in full longitudinal sections of crypts and villi and lamina propria as the number of positive apoptotic cells normalized to total number of cells present in crypts and villi and lamina propria, respectively.

Quantitative RT-PCR. Total RNA was purified and q-RT-PCR was done using an ABI 7900HT instrument (Applied Biosystems) as described (40).

Microarray analysis. Illumina Mouse-6 microarray was performed (Translational Genomics core, University of Connecticut Health Center) with the total RNA sample isolated from BM of Elavl1f/f and Elavl1Δ/Δ mice (n = 3). The chips contained approximately 48,000 transcripts from the mouse sequence-verified NIA 15k cDNA library plus the NIA 7.4k cDNA clone set (http://lgsun.grc.nia.nih.gov/cDNA/cDNA.html). Spot intensities were analyzed from scanned images using Scan Array Express (Perkin Elmer). Data were analyzed through the use of Ingenuity Pathways Analysis software suite (Ingenuity Systems).

Protein analysis. For IB analysis, protein extracts from murine tissues or cells were obtained by extraction in RIPA lysis buffer and processed as described (40).

Flow cytometry. All conjugated antibodies and secondary reagents used for flow cytometry were purchased from BD Biosciences or eBiosciences.

For analyses of early hematopoietic and lymphoid progenitors, samples were initially incubated with a cocktail of biotinylated antibodies against multiple mature hematopoietic lineage (Lin) markers, including CD3/CD4/CD8 (T lymphocytes), CD45R/B220 (B lymphocytes), CD11b (monocytes and macrophages), F4/80 (mature macrophages), Gr-1 (granulocytes), Ter119 (erythroid progenitors), and NK1.1 (natural killer cells). The samples were incubated at 4°C and then washed with staining media. As a second stage, samples were further incubated with streptavidin coupled to PECy7, Sca-1 coupled to FITC, CD117 coupled to allophycocyanin (APC), and CD127 coupled to PE. These 3 last antibodies label hematopoietic progenitors in the context of lineage-negative (Lin–) populations.

For analysis of B cell lineage development, samples were initially incubated with a biotinylated antibody against IgM, followed by a second step with PECy7-conjugated streptavidin, FITC-conjugated CD45R/B220, PE-conjugated CD19, and APC-conjugated CD117. For myeloid development, cell suspensions were stained with biotinylated anti-CD115 followed by a second step with PE-conjugated streptavidin, APC-conjugated CD11b, and FITC-conjugated Gr-1. For erythroid progenitor analysis, cell suspensions were stained with PE-conjugated Ter119 and, in certain experiments, together with APC-conjugated CD117.

Analysis of thymocytes was done by staining cell suspensions with anti-CD3 coupled to FITC, CD4 coupled to PE, and CD8 coupled to APC. In all the above described staining protocols, cells were suspended in a solution of staining media containing 1 mg/ml of propidium iodide (PI), and analyses were done after gating out dead cells.

For apoptosis, Vybrant Apoptosis assay kit containing Alexa Fluor 488 annexinV/PI was used according to manufacturer’s instruction. The cells were counterstained either with biotinylated anti-IgM, followed by PECy7-conjugated streptavidin and PE-conjugated anti-CD45R/B220 or CD4 coupled to PE plus CD8 coupled to APC. After staining, cells were resuspended in staining media containing PI. For analyses, cells positive for Annexin V and negative for PI were considered apoptotic, while cells double positive for PI and Annexin V were considered necrotic.

For cell proliferation assay, 4 hours after mice were injected with BrdU, cells were isolated from organs and stained initially with biotinylated anti-IgM followed by PE-conjugated streptavidin plus APC-conjugated CD45R/B220. Cells were then fixed in 95% ethanol, permeabilized in 1% paraformaldehyde/0.01% Tween-20, and treated with DNAse-I (Sigma-Aldrich). Finally, cells were stained with FITC-conjugated anti-BrdU antibody.

All analyses were done in a BD FACSCalibur flow cytometer, and data was processed using Cell Quest analysis package software.

Cell sorting. For sorting hematopoietic progenitors samples were first stained with biotinylated lineage cocktail followed by PECy7-conjugated streptavidin plus FITC-conjugated anti-Sca1, APC-conjugated CD117–Alexa Fluor 750, APC-conjugated CD127, and PE-conjugated CD135. LT-HSCs, ST-HSCs, and ELPs were sorted (41). For isolating B cells, BM suspensions were stained with biotinylated anti-IgM followed by APC- and Cy5.5-conjugated streptavidin plus FITC-conjugated CD45R/B220. Immature B cells (pre-pro, pro, and pre B cells) were sorted according to the phenotype CD45R/B220+IgM–, while more mature cells were defined as CD45R/B220+IgM+. All sorts were done in a BD FACS Aria equipped with 4 lasers and operated using the FACS Diva 6.0 software.

CFC assay. BM hematopoietic progenitor activity was evaluated as described (42).

Immunofluorescence. For immunostaining of cell-sorted population from BM, cells were cytospun, fixed, and stained with mouse monoclonal HuR antibody. Nucleic acid dye, TOPRO-3 (Molecular Probes) was used for nuclear staining. Slides were examined using a Zeiss LSM 510 Meta confocal microscope.

Generation and analysis of BM chimeras. Male CD45.1 recipient mice were irradiated with 2 doses of 5.0 Gy, 4 hours apart, and immediately reconstituted intravenously, via the tail vein, with CD45.2 BM cells from either Elavl1f/f or Elavl1f/f/Rosa-Cre-ERT2 mice. Chimerism was approximately 90%–96%, at 10 weeks after transplant. Recipient mice were given tamoxifen at 10 weeks after transplant for 3 days and monitored over a period of 16 days. Single cell suspensions of BM, thymus, and peripheral blood were prepared and stained with the following antibodies: Alexa 700 anti-CD19, APC-conjugated anti-B220, FITC -conjugated anti-IgM, PE -conjugated anti-CD117, PacificBlue anti-CD11b, APC-conjugated Alexa 750 or APC-conjugated anti-CD3, PE-conjugated anti-CD4, APC-conjugated anti-CD8, FITC-conjugated anti-Gr1, streptavidin anti-CD115, and APC-conjugated anti-CD45.2. Data gated on the CD45.2-positive fraction were acquired on an LSRII (BD) and analyzed using FlowJo (Tree Star).

Isolation and growth of MEFs. MEFs were isolated from intercrosses of Elavl1f/f or Elavl1f/f/Rosa-Cre-ERT2 mice at day 14 and cultured as described (43). For 4HT treatment, MEFs were grown in DMEM/MEM/10% FBS/1% antibiotics in presence of different doses of 4HT or ethanol as vehicle for different time intervals. 4HT was added fresh each day over a period of 14 days. For growth curve, cells were washed, trypsinized, and counted in a Coulter counter. For the transfection experiment with MEFs, cells were grown in presence of 2.5 μM 4HT or vehicle for 6 days, followed by transfection with either empty vector (pCMV6) or MDM-2 overexpression plasmid (pCMV6–Mdm-2, Origene, 1 μg of DNA) with Fugene, according to manufacturer’s instruction (Roche), and relative cell number was measured after 24, 48, 72 and 96 hours of transfection.

Mdm2 mRNA stability assay. MEFs from Elavl1f/f or Elavl1f/f/Rosa-Cre-ERT2 were grown in presence of 2.5 μM 4HT for 6 days. On day 6, 10 μg/ml of Actinomycin D (Sigma-Aldrich) was added, and total RNA was isolated at various time intervals and the Mdm2 mRNA level normalized to GAPDH was measured by q-RT-PCR.

Isolation of monocytes and PMNs. Total numbers of monocytes or PMNs were measured in peritoneal lavage fluid after 4 days or 4 hours of intraperitoneal injection of thioglycollate broth (3%), respectively.

Cell-cycle analysis. Total BM cells were isolated from Elavl1f/f or Elavl1f/f/Rosa-Cre-ERT2 mice fed with tamoxifen for 2 days. Total BM cells were sorted for progenitor population, fixed in ethanol and stained with PI in RNAse A buffer, and analyzed by flow cytometry. The distribution of cells between different phases of the cell cycle was determined by Modfit LT software.

Messenger ribonucleoprotein immunoprecipitation. Immunoprecipitation of endogenous Elavl1 mRNA complexes used to assess the association of the endogenous level of HuR with the endogenous level of Mdm2 mRNA was performed as described previously (44).

Statistics. All data were expressed as mean ± SEM. Paired 2-tailed Student’s t test was applied to determine statistical significance between 2 groups. P values of less than 0.05 were considered statistically significant.

Supplemental material

View Supplemental data

Acknowledgments

This work is supported by NIH grants HL49094 and CA-77839 to T. Hla. We thank Brent Graveley, Kamal Khanna, Shobha Thangada, Robert Clark, Elizabeth Wohlfert, and Guo-Hua Fong as well as Anupinder Kaur and Katie Lamothe for technical help and Gordon Carmichael, S.K. Dey, and Timothy F. Lane for critical comments.

Address correspondence to: Timothy Hla, Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Box 69, 1300 York Avenue, New York, New York, USA. Phone: (212) 746-9953; Fax: (212) 746-2830; E-mail: tih2002@med.cornell.edu. Or to: Hector Leonardo Aguila, Department of Immunology, University of Connecticut Health Center, 263 Farmington Ave., Farmington, Connecticut 06030, USA. Phone: (860) 679-7658; Fax: (860) 679-8130; E-mail: aguila@nso1.uchc.edu.

Footnotes

Conflict of interest: The authors have declared that no conflict of interest exists.

Reference information: J. Clin. Invest.119:3530–3543 (2009). doi:10.1172/JCI38263.

References
  1. Moore, M.J. 2005. From birth to death: the complex lives of eukaryotic mRNAs. Science. 309:1514-1518.
    View this article via: CrossRef PubMed Google Scholar
  2. Keene, J.D. 2007. RNA regulons: coordination of post-transcriptional events. Nat. Rev. Genet. 8:533-543.
    View this article via: CrossRef PubMed Google Scholar
  3. Bhattacharyya, S.N., Filipowicz, W. 2007. Argonautes and company: sailing against the wind. Cell. 128:1027-1028.
    View this article via: CrossRef PubMed Google Scholar
  4. Bhattacharyya, S.N., Habermacher, R., Martine, U., Closs, E.I., Filipowicz, W. 2006. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell. 125:1111-1124.
    View this article via: CrossRef PubMed Google Scholar
  5. Abdelmohsen, K., Lal, A., Kim, H.H., Gorospe, M. 2007. Posttranscriptional orchestration of an anti-apoptotic program by HuR. Cell Cycle. 6:1288-1292.
    View this article via: PubMed Google Scholar
  6. Brennan, C.M., Steitz, J.A. 2001. HuR and mRNA stability. Cell. Mol. Life Sci. 58:266-277.
    View this article via: CrossRef PubMed Google Scholar
  7. Gorospe, M. 2003. HuR in the mammalian genotoxic response: post-transcriptional multitasking. Cell Cycle. 2:412-414.
    View this article via: PubMed Google Scholar
  8. Dixon, D.A., et al. 2001. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J. Clin. Invest. 108:1657-1665.
    View this article via: JCI PubMed Google Scholar
  9. Sengupta, S., et al. 2003. The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. J. Biol. Chem. 278:25227-25233.
    View this article via: CrossRef PubMed Google Scholar
  10. Mazan-Mamczarz, K., et al. 2003. RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc. Natl. Acad. Sci. U. S. A. 100:8354-8359.
    View this article via: CrossRef PubMed Google Scholar
  11. Zou, T., et al. 2006. Polyamine depletion increases cytoplasmic levels of RNA-binding protein HuR leading to stabilization of nucleophosmin and p53 mRNAs. J. Biol. Chem. 281:19387-19394.
    View this article via: CrossRef PubMed Google Scholar
  12. Tong, X., Pelling, J.C. 2009. Enhancement of p53 expression in keratinocytes by the bioflavonoid apigenin is associated with RNA-binding protein HuR. Mol. Carcinog. 48:118-129.
    View this article via: CrossRef PubMed Google Scholar
  13. Erkinheimo, T.L., et al. 2003. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res. 63:7591-7594.
    View this article via: PubMed Google Scholar
  14. Heinonen, M., et al. 2005. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res. 65:2157-2161.
    View this article via: CrossRef PubMed Google Scholar
  15. Mrena, J., et al. 2005. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin. Cancer Res. 11:7362-7368.
    View this article via: CrossRef PubMed Google Scholar
  16. Katsanou, V., et al. 2005. HuR as a negative posttranscriptional modulator in inflammation. Mol. Cell. 19:777-789.
    View this article via: CrossRef PubMed Google Scholar
  17. Levadoux-Martin, M., et al. 2003. Impaired gametogenesis in mice that overexpress the RNA-binding protein HuR. EMBO Rep. 4:394-399.
    View this article via: CrossRef PubMed Google Scholar
  18. Katsanou, V., et al. 2009. The RNA-binding protein Elavl1/HuR is essential for placental branching morphogenesis and embryonic development. Mol. Cell. Biol. 29:2762-2776.
    View this article via: CrossRef PubMed Google Scholar
  19. Tang, S.H., Silva, F.J., Tsark, W.M., Mann, J.R. 2002. A Cre/loxP-deleter transgenic line in mouse strain 129S1/SvImJ. Genesis. 32:199-202.
    View this article via: CrossRef PubMed Google Scholar
  20. Takeda, K., Cowan, A., Fong, G.H. 2007. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation. 116:774-781.
    View this article via: CrossRef PubMed Google Scholar
  21. Morrison, S.J., Weissman, I.L. 1994. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity. 1:661-673.
    View this article via: CrossRef PubMed Google Scholar
  22. Spangrude, G.J., Heimfeld, S., Weissman, I.L. 1988. Purification and characterization of mouse hematopoietic stem cells. Science. 241:58-62.
    View this article via: CrossRef PubMed Google Scholar
  23. Kondo, M., et al. 2000. Cell-fate conversion of lymphoid-committed progenitors by instructive actions of cytokines. Nature. 407:383-386.
    View this article via: CrossRef PubMed Google Scholar
  24. Hardy, R.R., Hayakawa, K. 2001. B cell development pathways. Annu. Rev. Immunol. 19:595-621.
    View this article via: CrossRef PubMed Google Scholar
  25. Akashi, K., Traver, D., Miyamoto, T., Weissman, I.L. 2000. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature. 404:193-197.
    View this article via: CrossRef PubMed Google Scholar
  26. Jacquin, C., Gran, D.E., Lee, S.K., Lorenzo, J.A., Aguila, H.L. 2006. Identification of multiple osteoclast precursor populations in murine bone marrow. J. Bone Miner. Res. 21:67-77.
    View this article via: CrossRef PubMed Google Scholar
  27. Kina, T., et al. 2000. The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br. J. Haematol. 109:280-287.
    View this article via: CrossRef PubMed Google Scholar
  28. Zuniga-Pflucker, J.C., Lenardo, M.J. 1996. Regulation of thymocyte development from immature progenitors. Curr. Opin. Immunol. 8:215-224.
    View this article via: CrossRef PubMed Google Scholar
  29. Vermes, I., Haanen, C., Steffens-Nakken, H., Reutelingsperger, C. 1995. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods. 184:39-51.
    View this article via: CrossRef PubMed Google Scholar
  30. Christensen, J.L., Weissman, I.L. 2001. Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. Proc. Natl. Acad. Sci. U. S. A. 98:14541-14546.
    View this article via: CrossRef PubMed Google Scholar
  31. Calvano, S.E., et al. 2005. A network-based analysis of systemic inflammation in humans. Nature. 437:1032-1037.
    View this article via: CrossRef PubMed Google Scholar
  32. Levine, A.J., Hu, W., Feng, Z. 2006. The P53 pathway: what questions remain to be explored? Cell Death Differ. 13:1027-1036.
    View this article via: CrossRef PubMed Google Scholar
  33. Montgomery, R.K., Breault, D.T. 2008. Small intestinal stem cell markers. J. Anat. 213:52-58.
    View this article via: CrossRef PubMed Google Scholar
  34. Sharpless, N.E. 2005. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat. Res. 576:22-38.
    View this article via: PubMed Google Scholar
  35. Blackshear, P.J. 2002. Tristetraprolin and other CCCH tandem zinc-finger proteins in the regulation of mRNA turnover. Biochem. Soc. Trans. 30:945-952.
    View this article via: CrossRef PubMed Google Scholar
  36. Dean, J.L., Sully, G., Clark, A.R., Saklatvala, J. 2004. The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal. 16:1113-1121.
    View this article via: CrossRef PubMed Google Scholar
  37. Saklatvala, J., Dean, J., Clark, A. 2003. Control of the expression of inflammatory response genes. Biochem. Soc. Symp. 70:95-106.
    View this article via: PubMed Google Scholar
  38. Lopez de Silanes, I., Lal, A., Gorospe, M. 2005. HuR: post-transcriptional paths to malignancy. RNA Biol. 2:11-13.
    View this article via: PubMed Google Scholar
  39. Kim, H.H., et al. 2009. HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev. 23:1743-1748.
    View this article via: CrossRef PubMed Google Scholar
  40. Ghosh, M., et al. 2007. COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. J. Exp. Med. 204:2053-2061.
    View this article via: CrossRef PubMed Google Scholar
  41. Kondo, M., Weissman, I.L., Akashi, K. 1997. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell. 91:661-672.
    View this article via: CrossRef PubMed Google Scholar
  42. Takeda, K., et al. 2008. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood. 111:3229-3235.
    View this article via: CrossRef PubMed Google Scholar
  43. Sun, H., et al. 1999. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 96:6199-6204.
    View this article via: CrossRef PubMed Google Scholar
  44. Abdelmohsen, K., et al. 2007. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol. Cell. 25:543-557.
    View this article via: PubMed Google Scholar
Version history
  • Version 1 (November 2, 2009): No description
  • Version 2 (December 1, 2009): No description
Advertisement
Advertisement